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Abstract
Background: The aims of this study were to evaluate the impact of initial uterus-preserving surgery, such as
myomectomy or subtotal hysterectomy, on the recurrence rates of patients with uterine sarcoma found incidentally
and to investigate the role of surgical re-exploration in this disease subset.
Methods: We performed a retrospective chart review for patients who had previously undergone either total
hysterectomy or subtotal hysterectomy or myomectomy at the time of initial surgery for presumed benign uterine
leiomyoma and were found to have uterine sarcoma on final pathology. Survival analysis was performed comparing
patients according to the type of initial surgery.
Results: Between 2006 and 2014, 45 patients with uterine sarcoma were identified. Myomectomy or subtotal
hysterectomy was performed in 15 patients, and 30 patients underwent total hysterectomy as the initial surgery. Of the
patients who underwent myomectomy or subtotal hysterectomy as the initial surgery (n = 15), 14 were re-explored to
complete staging. Of the patients who underwent re-exploration (n = 14), five (35.8 %) had remnant sarcoma on the
remaining uterus and no patients had disseminated disease. A Kaplan–Meier curve and log-rank test showed no
difference in progression-free survival (P = 0.941) between the two groups.
Conclusion: Initial uterus-preserving surgery does not appear to be associated with an adverse impact on survival
outcomes for unexpected uterine sarcoma when surgical re-exploration was performed immediately. As such, surgical
re-exploration may be useful for removing any remnant sarcoma.
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Background
Uterine leiomyomas are the most common benign uter-
ine tumors [1]. A range of symptoms, from abnormal
bleeding to pelvic pressure, are associated with uterine
leiomyomas. Surgical management, either myomectomy
or hysterectomy, is often required for the management
of this form of disease. Surgical options depend on vari-
ous factors, including age, childbearing requirements
and patients’ preferences. Myomectomy is often a good
surgical choice for patients of reproductive age who wish
to bear children. Furthermore, approximately half of
women with leiomyoma prefer uterus-preserving treat-
ment, even after childbearing is completed [2].
Myomectomy or subtotal hysterectomy is the one of
the most commonly performed gynecologic surgeries.
With recent advances in minimally invasive surgery, lap-
aroscopic myomectomies or hysterectomies have be-
come common practices. Although a major concern
with laparoscopic surgery is the removal of large myoma
through small incisions, the introduction of morcellation
has solved this problem. However, the US Food and
Drug Administration (FDA) has issued a statement dis-
couraging the use of power morcellation for hysterec-
tomy and myomectomy due to the fear of potentially
disseminating an occult uterine sarcoma [3].
In uterus-preserving surgery, such as myomectomy or
subtotal hysterectomy, there may be concerns about tumor
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aggression, even when morcellation is not used. However,
there is limited literature on the management of uterine
sarcoma found incidentally after myomectomy or subtotal
hysterectomy for presumed uterine leiomyoma [4, 5]. The
aims of this study were to evaluate the outcomes of patients
with uterine sarcoma found incidentally after initial uterus-
preserving surgery for presumed benign disease and to
investigate the role of surgical re-exploration in this disease
subset.
Methods
After gaining approval from the Institutional Review
Board of Yonsei University Hospital (Registration num-
ber: 4-2015-0896), we performed a retrospective chart
review for patients who had previously undergone either
total hysterectomy or subtotal hysterectomy or myomec-
tomy at the time of initial surgery for presumed benign
uterine leiomyoma and were found to have uterine sar-
coma on final pathology at the Department of Obstetrics
and Gynecology of Yonsei University Hospital, Seoul,
Korea between 2006 and 2014.
Study data were collected from patients’ medical
charts: age at diagnosis, gravidity, parity, menopausal
status, final pathology, stage, type of primary and sec-
ondary surgeries, date of surgery, postoperative adju-
vant therapy, disease status, location of recurrence and
follow-up interval. Intraoperative morcellation was in-
troduced in our department in 2006 as a technique for
extracting myomas or the uterus from the abdominal
cavity during surgical management. Morcellation tech-
niques include the use of scalpel or scissors in vaginal
surgeries (hand morcellation) and a power morcellator
in laparoscopy. The open morcellation techinique was
performed during the study period, although the in-bag
morcellation technique was adopted in 2014. Our insti-
tution has since adopted a policy of surgical re-
exploration in patients with morcellated sarcoma and/
or incomplete surgery, such as myomectomy or sub-
total hysterectomy. The type of surgery used at re-
exploration depends on each surgeon’s preferences. As
a minimum, this includes the removal of the remaining
uterus and exploration of the abdominal cavity. Ovarian
preservation is considered in young premenopausal
women with early-stage sarcomas. Stages are assigned
in accordance with the 2009 FIGO staging systems.
All available hematoxylin and eosin-stained slides
were reviewed by an independent gynecologic patholo-
gist (H. S. Kim), who was blind to patient outcomes.
All endometrial stromal sarcoma cases were diagnosed
as low-grade endometrial stromal sarcoma based on
characteristic histopathological features and uniform
immunoreactivity for CD10, which is an endometrial
stromal cell marker.
Statistical analysis
Descriptive statistics were tabulated by patient group. Con-
tinuous variables were summarized by using either standard
deviations or medians with ranges. Categorical variables
were compared using the chi-square test or Fisher’s exact
test. Progression-free survival (PFS) was defined as the time
from the date of first treatment to the first occurrence of a
local or distant recurrence. PFS was estimated using the
Kaplan–Meier method, and differences in survival were
compared using the log-rank test. Survival analysis was per-
formed comparing patients according to the type of initial
surgery and the use of morcellation.
All analyses were performed using STATA version 12.0
(StataCorp, College Station, TX, US). A two-sided P value
of less than 0.05 was considered statistically significant.
Results
Patient characteristics
During the study period, 62 patients were diagnosed with
uterine sarcoma. Seven of those patients had definite meta-
static lesion at diagnosis and 10 underwent staging opera-
tions during initial surgery based on the frozen results. As
such, 45 patients were diagnosed with unexpected uterine
sarcoma after the initial surgery for presumed leiomyoma
(Fig. 1). For 22 patients, primary surgery was performed by
a general gynecologist at a different institution and the case
was then referred to our center after initial management.
For 23 patients, surgery was performed by two general gy-
necologists and five gynecologic oncologists within the
Yonsei University Health System. Over two thirds of pa-
tients (n = 31; 68.9 %) underwent open surgery and 14
underwent laparoscopy (31.1 %). Myomectomy or subtotal
hysterectomy were performed in 15 patients (33.3 %), while
30 patients (66.7 %) underwent total hysterectomy as the
initial surgery. Of the patients who underwent myomec-
tomy or subtotal hysterectomy as the initial surgery (n =
15), 14 (93.3 %) were re-explored to staging operation with
total hysterectomy. Of the patients who underwent total
hysterectomy as the initial surgery, nine (30.0 %) were re-
explored to complete the staging operation. The rate of ad-
juvant therapy was 33.3 % (5/15) in patients who under-
went myomectomy or subtotal hysterectomy and 50 %
(15/30) in patients who underwent total hysterectomy.
The baseline characteristics are shown in Table 1. Hand
morcellation was performed in five patients who underwent
laparoscopic hysterectomy as the initial surgery, while
power morcellation was performed in four patients who
underwent laparoscopic myomectomy or subtotal hysterec-
tomy as the initial surgery. Of the nine patients with mor-
cellated uterine sarcoma at the initial surgery, one, who had
previously undergone hysterectomy, had disseminated dis-
ease that was detected during immediate surgical re-
exploration. Of the four patients who underwent power
morcellation of the uterine sarcoma during the initial
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uterus-preserving surgery, none were identified as having
disseminated disease during immediate surgical re-
exploration.
Survival
The median follow-up duration was 41 months.
Among the patients with sarcoma, 10 (18.2 %) experi-
enced recurrence, with a mean time to progression of
11.8 months. Recurrences were localized to the pelvis
in three patients and to the paraaortic nodes in one
patient, while six patients presented with distant dis-
ease (two lung; one hepatic), including two patients
with multisite dissemination. During follow-up, five of
the patients with sarcoma (50 %) died of the disease.
PFS was analyzed according to the type of initial surgery
(myomectomy/subtotal hysterectomy vs. hysterectomy) and
considering the possibility of tumor aggression in cases of
uterus-preserving surgery, even without morcellation. The
Kaplan–Meier curves and log-rank test showed no differ-
ence in PFS (P = 0.941) between patients who underwent
myomectomy or subtotal hysterectomy and those who
underwent total hysterectomy as the initial surgery (Fig. 2a).
We analyzed outcomes in the morcellation and non-
morcellation groups and found significant differences in
outcomes (P = 0.048) (Additional file 1: Figure S1). In the
non-morcellation group, recurrence was observed in five
patients (13.4 %), while in the morcellation group, recur-
rence was found in three patients (33.3 %). In the myomec-
tomy/subtotal hysterectomy group, the morcellation
subgroup had poorer outcomes than the non-morcellation
subgroup (P = 0.051) (Additional file 1: Figure S2). In
addition, we did subgroup analysis to identify whether sur-
vival differences exist between myomectomy and subtotal
hysterectomy. We found no significant differences in out-
comes (P = 0.882) (Additional file 1: Figure S3).
Role of re-exploration
In the myomectomy/subtotal hysterectomy group, the
majority of patients underwent re-exploration to complete
the staging operation and remove the remaining uterus.
The mean time interval between initial surgery and re-
exploration was 18 days. All cases of re-exploration were
achieved within 21 days. No major complications were
found perioperatively. Five patients (35.8 %) had remnant
sarcoma in the remaining uterus and none were upstaged
as a result of the staging operation. Ascites or gross meta-
static lesions were not found during re-exploration. De-
tailed information on the patients in these groups is
shown in Table 2. Of all the re-exploration cases, 11
(76.8 %) were alive without disease.
Discussion
In this study, we compared the outcomes of uterine sar-
coma found incidentally in terms of the type of initial
surgery used (uterus-preserving surgery vs. hysterec-
tomy). Despite concerns about tumor aggression in cases
of uterus-preserving surgery, even without morcellation,
initial uterus-preserving surgery does not appear to be
associated with an adverse impact on survival outcomes
for unexpected uterine sarcoma. Immediate surgical re-
exploration after uterus-preserving surgery makes it pos-
sible to remove remnant sarcoma in the remaining
uterus.
Myomectomy is the treatment of choice for uterine
myoma when the patient wants to bear children in the
future. For women who have completed childbearing,
hysterectomy is typically considered to be the surgical
treatment of choice for leiomyoma given the risk of re-
currence after myomectomy with uterine preservation.
However, many women wish to preserve the uterus even
after the completion of childbearing. A US survey
showed that approximately half of women aged 40–59
believed that uterine preservation was important when
considering treatment options for myoma [2]. Many
women express concern about the consequences of hys-
terectomy, including changes to function, emotions and
behavior. For these women, myomectomy could be an
alternative to hysterectomy, even considering the risk of
recurrence or re-operation [6]. Traditional subtotal hys-
terectomy continues to be performed for a variety of
Fig. 1 Flow diagram in patients with incidentally found uterine sarcoma
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indications, including patient preference and, in patients
with challenging anatomy, surgeon preference, reflecting
the technical difficulty of removing the cervix [7].
Myomectomy can be performed hysteroscopically, ab-
dominally through a laparotomy, or, more recently, via a
minimally invasive surgical approach with laparoscopic
or robotic assistance. The removal of large leiomyoma
through the small incisions used for minimally invasive
myomectomy often poses a challenge. Large leiomyoma
can be removed through a small abdominal incision, va-
ginally by colpotomy or through the use of power mor-
cellation to fragment the leiomyoma. A recent Cochrane
review showed that women who underwent minimally
invasive surgery had significantly less blood loss, fewer
incisional infections or febrile episodes, shorter hospital
stays and speedier return to normal activities than those
who underwent laparotomy [8]. Power morcellation
plays an important role in the extraction of large leio-
myoma from the abdominal cavity during minimally in-
vasive surgery. However, following reports of poor
outcomes in patients with inadvertently morcellated
uterine sarcoma, the FDA has discouraged the use of
laparoscopic power morcellation during hysterectomy or
myomectomy for uterine fibroids.
Based on the literature, the FDA has reported that one
in 352 women have unsuspected uterine sarcoma while
undergoing surgery for presumed benign disease [3].
Sarcoma prevalence estimates are highly dependent on
age, with the lowest prevalence among women under
the age of 50 and the highest prevalence among women
older than 60 [9]. As myomectomies are usually per-
formed in the younger age group, the actual incidence of
uterine sarcoma after myomectomy would appear to be
lower than expected. The risk of cancer in women who
undergo myomectomy performed using power morcella-
tion is lower than that reported for hysterectomy. The
prevalence of uterine cancer has been found to be
0.19 % (1 in 528) in women who undergo myomectomy
without morcellation and 0.09 % (1 in 1073) in those
who undergo power morcellation [10]. Therefore, in pa-
tients with unexpected uterine sarcoma after uterus-
preserving surgery, tumor aggression resulting from ini-
tial surgery without power morcellation may be more
common than tumor dissemination with power
morcellation.
Recent National Comprehensive Cancer Network
(NCCN) guidelines recommend en bloc tumor resec-
tion without tumor disruption as the standard treat-
ment for localized sarcoma, which is consistent with
the accepted management principles for soft tissue
sarcoma arising in any anatomical location [11]. In
uterus-preserving surgery, there may be concerns
about tumor disruption associated with surgery or any
remaining tumor. Therefore, patients who have under-
gone uterus-preserving surgery for presumed benign
uterine disease and are found to have sarcoma on final
pathology represent a management dilemma. However,
few studies assess the prognosis for unexpected uter-
ine sarcoma after myomectomy [4, 5].
Table 1 Patient characteristics
Characteristics Myomectomy or subtotal
hysterectomy (n = 15)
Hysterectomy
(n = 30)
Age (years)
median (range)
42 (27–54) 47 (26–66)
Gravidity,
median (range)
3 (0–6) 3 (0–6)
≤ 2 6 (40 %) 9 (30 %)
> 2 9 (60 %) 21 (70 %)
Parity, median (range) 2 (0–3) 2 (0–4)
≤ 1 7 (46.7 %) 7 (30.3 %)
> 1 8 (53.3 %) 23 (76.7 %)
Menopause
Yes 4 (26.7 %) 14 (46.7 %)
No 11 (73.3 %) 16 (53.3 %)
Previous cesarean section
Yes 3 (20 %) 4 (13.3 %)
No 12 (80 %) 26 (86.7 %)
Mode of initial surgery
Laparotomy 9 (60 %) 22 (73.3 %)
Laparoscopy 6 (40 %) 8 (26.7 %)
FIGO stage
IA 5 (33.3 %) 7 (23.3 %)
IB 9 (60.0 %) 22 (73.3 %)
IIA 1 (6.7 %) 1 (3.3 %)
Histology
Leiomyosarcoma 7 (46.7 %) 11 (36.7 %)
Endometrial
stromal sarcoma
7 (46.7 %) 19 (63.3 %)
Adenosarcoma 1 (6.7 %) 0
Morcellation*
No 11 (73.3 %) 25 (83.3 %)
Hand morcellation 0 (0 %) 5 (16.7 %)
Power
morcellation
4 (26.7 %) 0 (0 %)
Surgical re-exploration*
Yes 14 (93.3 %) 9 (30 %)
No 1 (6.7 %) 21 (70 %)
Adjuvant therapy
No 10 (66.7 %) 15 (50 %)
Radiation 1 (6.7 %) 5 (16.7 %)a
Chemotherapy 4 (26.7 %) 14 (46.7 %)a
*P < 0.05
a4 patients underwent concurrent chemoradiation
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Zhang et al. reported the outcomes of nine patients with
unexpected uterine sarcoma after myomectomy [5]. Eight
patients underwent a secondary operation, and endometrial
stromal sarcoma was the dominant subtype of unexpected
uterine sarcoma in the study. All patients were alive and
there was only one case of local recurrence in the preserved
ovary. Cusido et al. reported no significant difference in
prognosis for uterine sarcoma in terms of myomectomy
versus hysterectomy as the initial surgery [4]. Of the 14 pa-
tients who underwent myomectomy in this study, eight
(57 %) underwent a secondary operation with hysterec-
tomy. In terms of PFS, no statistical differences were found
in our study. In addition, our results suggest that there may
be benefits to surgical re-exploration. Of the patients who
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Fig. 2 Progression-free survival of patients with unexpected sarcoma stratified by type of initial surgery (myomectomy/subtotal hysterectomy vs.
total hysterectomy)
Table 2 Clinicopathologic features of patients with unexpected uterine sarcoma after myomectomy or subtotal hysterectomy for
presumed uterine leiomyoma
Patient Initial surgery Site of operation Morcellation Histology Surgical re-exploration Remnant tumor State
1 Lap M participating institution Yes LMS TAH + BSO + Om+ PLND + PALND No AWD
2 Open M outside institution No LMS TAH + BSO + Om+ PLND + PALND No NED
3 Lap subH outside institution Yes LMS TAH + BSO + PLND No D
4 Open subH outside institution No LMS TAH + BSO + Om+ PLND + Appe No NED
5 Open M outside institution No LMS TAH + BSO + Om No NED
6 Open subH outside institution No LMS TAH + BSO + Om+ PLND + PALND + Appe No NED
7 Open M outside institution No LMS TAH + LSO + Om+ PLND + Appe No AWD
8 Open M outside institution No ESS TAH + BSO + Om+ PLND + Appe Yes NED
9 Open subH outside institution No ESS TAH + LSO + Om+ PLND + Appe Yes NED
10 Lap M outside institution Yes ESS TLH + LSO + PLND Yes NED
11 Lap M outside institution Yes ESS TLH + BSO + PLND + PALND + Appe No NED
12 Open subH outside institution No ESS TAH + BSO+ Om+ PLND + PALND No NED
13 Lap M participating institution No AS TLH + RSO + PLND Yes NED
14 Lap M participating institution No ESS No N/A NED
15 Open M outside institution No ESS TAH + BSO Yes NED
Lap M laparoscopic myomectomy, Open M open myomectomy, Lap subH laparoscopic subtotal hysterectomy, Open subH Open subtotal hysterectomy, AWD alive
with disease, D death from disease, NED no evidence of disease, TAH total abdominal hysterectomy, TLH total laparoscopic hysterectomy, BSO bilateral salpingo-
oophorectomy, LSO left salpingo-oophorectomy, RSO right salpingo-oophorectomy, Om omentectomy, PLND pelvic lymphadenectomy, PALND paraaortic lymphad-
enectomy, Appe appendectomy, LMS leiomyosarcoma, ESS endometrial stromal sarcoma, AS adenosarcoma
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underwent re-exploration at a referral institution after myo-
mectomy or subtotal hysterectomy, approximately 35.8 %
had remnant sarcoma on the remaining uterus. However,
the value of lymphadenectomy, appendectomy or omen-
tectomy for identifying occult metastasis in early-stage uter-
ine sarcoma appears to be low.
Regarding morcellation, our results are consistent with
previous studies showing poorer outcomes with morcella-
tion in uterine sarcoma. Concerns have been raised as
uterine morcellation carries a risk of disseminating unex-
pected malignancy with an apparent associated increase in
mortality [12]. Previous studies have shown that morcella-
tion has a negative impact on survival outcomes in uterine
sarcoma [12, 13]. Taking into consideration the negative
impact of morcellation in sarcomas, this technique should
be used with caution in patients with suspicious uterine
sarcoma.
Conclusions
Initial uterus-preserving surgery does not appear to be as-
sociated with an adverse impact on survival outcomes for
unexpected uterine sarcoma when surgical re-exploration
is performed immediately. In our opinion, myomectomy or
subtotal hysterectomy remain the preferred options for
treating women with presumed leiomyoma who want to
preserve the uterus as no difference in survival was found
between uterus-preserving surgery and total hysterectomy,
even in cases with unexpected sarcoma. Our second rec-
ommendation is that patients who undergo myomectomy
or subtotal hysterectomy where uterine sarcoma is de-
tected on final pathology undergo immediate surgical re-
exploration. Surgical re-exploration appears to be useful
for removing remnant sarcoma in the remaining myome-
trium, which is a key factor for improving outcomes in this
disease subset. Further large-scale studies are required to
document the outcomes of unexpected uterine sarcoma
with or without morcellation after uterus-preserving
surgery.
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